According to the drug patent watch website [1], the patent for Lipitor expired in 2011, and the drug is now available in generic form, which is generally less expensive than brand-name drugs. The Journal of Ethics [2] discusses the uniqueness and authenticity of Lipitor and how it has been marketed to stand out from its substitutes, but it does not provide information on the relative cost of Lipitor compared to its substitutes. However, the British Heart Foundation [3] lists several alternatives to Lipitor, including simvastatin, atorvastatin, and pravastatin, which are all available in generic form and are generally less expensive than brand-name drugs. Therefore, it can be concluded that Lipitor is likely to be more expensive than its generic substitutes, but the cost may vary depending on the specific substitute chosen.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LIPITOR
[2] https://journalofethics.ama-assn.org/article/me-there-no-substitute-authenticity-uniqueness-and-lessons-lipitor/2010-10
[3] https://www.bhf.org.uk/informationsupport/heart-matters-magazine/medical/cholesterol-lowering-alternatives